IT1362675B - N-idrossiammidi -sostituiti con gruppi triciclici come inibitori dell'istone deacelitasi,loro preparazione ed impiego in formulazioni farmaceutiche - Google Patents

N-idrossiammidi -sostituiti con gruppi triciclici come inibitori dell'istone deacelitasi,loro preparazione ed impiego in formulazioni farmaceutiche

Info

Publication number
IT1362675B
IT1362675B ITFI20050042A IT1362675B IT 1362675 B IT1362675 B IT 1362675B IT FI20050042 A ITFI20050042 A IT FI20050042A IT 1362675 B IT1362675 B IT 1362675B
Authority
IT
Italy
Prior art keywords
deacelitasis
hydroxyamides
islands
inhibitors
substituted
Prior art date
Application number
Other languages
English (en)
Inventor
Tula Dimoulas
Danilo Giannotti
Antonio Guidi
Nicholas Harmat
Original Assignee
Menarini Internat Operations Luxembourg Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Menarini Internat Operations Luxembourg Sa filed Critical Menarini Internat Operations Luxembourg Sa
Priority to IT000042 priority Critical patent/IT1362675B/it
Priority to TW095107553A priority patent/TW200719900A/zh
Priority to EP06708743A priority patent/EP1863776A1/en
Priority to BRPI0608549-0A priority patent/BRPI0608549A2/pt
Priority to JP2008501283A priority patent/JP2008533088A/ja
Priority to PCT/EP2006/060661 priority patent/WO2006097449A1/en
Priority to CNA2006800082490A priority patent/CN101142197A/zh
Priority to CA002600521A priority patent/CA2600521A1/en
Priority to KR1020077023278A priority patent/KR20080003336A/ko
Priority to AU2006222883A priority patent/AU2006222883A1/en
Priority to AP2007004170A priority patent/AP2007004170A0/xx
Priority to EA200701969A priority patent/EA013015B1/ru
Priority to US11/886,168 priority patent/US20080275023A1/en
Priority to MX2007011071A priority patent/MX2007011071A/es
Priority to ARP060100976A priority patent/AR053171A1/es
Priority to SA06270133A priority patent/SA06270133B1/ar
Publication of ITFI20050042A1 publication Critical patent/ITFI20050042A1/it
Priority to NI200700222A priority patent/NI200700222A/es
Priority to IL185879A priority patent/IL185879A0/en
Priority to MA30292A priority patent/MA29673B1/fr
Priority to ZA200708754A priority patent/ZA200708754B/xx
Priority to CO07107398A priority patent/CO6321131A2/es
Priority to NO20075229A priority patent/NO20075229L/no
Application granted granted Critical
Publication of IT1362675B publication Critical patent/IT1362675B/it

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/38—[b, e]- or [b, f]-condensed with six-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/16—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D267/20—[b, f]-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D281/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D281/16—[b, f]-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/36—Seven-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D291/00—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms
    • C07D291/08—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
IT000042 2005-03-15 2005-03-15 N-idrossiammidi -sostituiti con gruppi triciclici come inibitori dell'istone deacelitasi,loro preparazione ed impiego in formulazioni farmaceutiche IT1362675B (it)

Priority Applications (22)

Application Number Priority Date Filing Date Title
IT000042 IT1362675B (it) 2005-03-15 2005-03-15 N-idrossiammidi -sostituiti con gruppi triciclici come inibitori dell'istone deacelitasi,loro preparazione ed impiego in formulazioni farmaceutiche
TW095107553A TW200719900A (en) 2005-03-15 2006-03-07 N-hydroxyamides ω-substituted with tricyclic groups as histone deacetylase inhibitors, their preparation and use in pharmaceutical formulations
MX2007011071A MX2007011071A (es) 2005-03-15 2006-03-13 N-hidroxiamidas omega-sustituidas con grupos triciclicos como inhibidores de histona desacetilasa, su preparacion y uso en formulaciones farmaceuticas.
JP2008501283A JP2008533088A (ja) 2005-03-15 2006-03-13 ヒストンデアセチラーゼ阻害剤としての、三員環基でω位置換したＮ−ヒドロキシアミド、その調製方法、及び医薬組成物への使用
PCT/EP2006/060661 WO2006097449A1 (en) 2005-03-15 2006-03-13 N-hydroxyamides omega-substituted with tricyclic groups as histone deacetylase inhibitors, their preparation and use in pharmaceutical formulations
CNA2006800082490A CN101142197A (zh) 2005-03-15 2006-03-13 作为组蛋白去乙酰基酶抑制剂的3环基团ω-取代的N-羟酰胺及其制备方法以及在药物配方中的用途
CA002600521A CA2600521A1 (en) 2005-03-15 2006-03-13 N-hydroxyamides omega-substituted with tricyclic groups as histone deacetylase inhibitors, their preparation and use in pharmaceutical formulations
KR1020077023278A KR20080003336A (ko) 2005-03-15 2006-03-13 히스톤 탈아세틸화제 저해제로서 삼중환기로 오메가-치환된엔-히드록시아미드, 그 제조 방법 및 약학적 제제로서의용도
AU2006222883A AU2006222883A1 (en) 2005-03-15 2006-03-13 N-hydroxyamides omega-substituted with tricyclic groups as histone deacetylase inhibitors, their preparation and use in pharmaceutical formulations
AP2007004170A AP2007004170A0 (en) 2005-03-15 2006-03-13 N-hydroxyamides omega-substituted with tricyclic groups as histone deacetylase inhibitors, their preparation and use in pharmaceutical formulations
EP06708743A EP1863776A1 (en) 2005-03-15 2006-03-13 N-hydroxyamides omega-substituted with tricyclic groups as histone deacetylase inhibitors, their preparation and use in pharmaceutical formulations
US11/886,168 US20080275023A1 (en) 2005-03-15 2006-03-13 N-Hydroxyamides Omege-Substituted with Tricyclic Groups as Histone Deacetylase Inhibitors, Their Preparation and Use in Pharmaceutical Formulations
BRPI0608549-0A BRPI0608549A2 (pt) 2005-03-15 2006-03-13 inibidores da enzima histona deacetilase à base de n-hidroxiamidas (omega)-substituìdas por grupos tricìclicos
EA200701969A EA013015B1 (ru) 2005-03-15 2006-03-13 N-ГИДРОКСИАМИДЫ, ω-ЗАМЕЩЕННЫЕ ТРИЦИКЛИЧЕСКИМИ ГРУППАМИ, КАК ИНГИБИТОРЫ ГИСТОНДЕАЦЕТИЛАЗЫ, ИХ ПОЛУЧЕНИЕ И ПРИМЕНЕНИЕ В ФАРМАЦЕВТИЧЕСКИХ ФОРМАХ
ARP060100976A AR053171A1 (es) 2005-03-15 2006-03-14 N-hidroxiamidas omega-sustituidos con grupos triciclicos como inhibidores de la histona deacetilasa sus preparaciones y empleo en formulaciones farmaceuticas
SA06270133A SA06270133B1 (ar) 2005-03-15 2006-05-08 تحضير مركبات n- هيدروكسي أميد تحمل بدائل عند الموقع أوميغا من مجموعات ثلاثسة الحلقه بصفتها مثبطات لهستون دياستيلاز واستخدامها في التراكيب الصيدلانية
NI200700222A NI200700222A (es) 2005-03-15 2007-08-23 N-hydroxiamidas omega-sustituidas con grupos triciclicos como inhibidores de histona de desacetilasa, su preparación y su uso en formulaciones farmacéuticas.
IL185879A IL185879A0 (en) 2005-03-15 2007-09-10 N-hydroxyamides omega-substituted with tricyclic groups as histone deacetylase inhibitors, their preparation and use in pharmaceutical formulations
MA30292A MA29673B1 (fr) 2005-03-15 2007-10-11 N-hydroxyamides omega-substitues par des groupes tricycliques, servant d'inhibiteurs d'histone desacetylase, leur preparation et leur utilisation dans des formulations pharmaceutiques
ZA200708754A ZA200708754B (en) 2005-03-15 2007-10-12 N-hydroxyamides omega-substituted with tricyclic groups as histone deacetylase inhibitors, their preparation and use in pharmaceutical formulations
CO07107398A CO6321131A2 (es) 2005-03-15 2007-10-12 N-hidroxiamidas omega- sustituidas con grupos triciclicos como inhibidores de histona desacetilasa su preparacion y uso en formulaciones farmaceuticas
NO20075229A NO20075229L (no) 2005-03-15 2007-10-12 N-hydroksyamider omega-substituert med trisykliske grupper som histondeacetylasehemmere, deres fremstilling og anvendelse i farmasoytiske formuleringer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT000042 IT1362675B (it) 2005-03-15 2005-03-15 N-idrossiammidi -sostituiti con gruppi triciclici come inibitori dell'istone deacelitasi,loro preparazione ed impiego in formulazioni farmaceutiche

Publications (2)

Publication Number Publication Date
ITFI20050042A1 ITFI20050042A1 (it) 2006-09-16
IT1362675B true IT1362675B (it) 2009-06-25

Family

ID=36676439

Family Applications (1)

Application Number Title Priority Date Filing Date
IT000042 IT1362675B (it) 2005-03-15 2005-03-15 N-idrossiammidi -sostituiti con gruppi triciclici come inibitori dell'istone deacelitasi,loro preparazione ed impiego in formulazioni farmaceutiche

Country Status (22)

Country Link
US (1) US20080275023A1 (it)
EP (1) EP1863776A1 (it)
JP (1) JP2008533088A (it)
KR (1) KR20080003336A (it)
CN (1) CN101142197A (it)
AP (1) AP2007004170A0 (it)
AR (1) AR053171A1 (it)
AU (1) AU2006222883A1 (it)
BR (1) BRPI0608549A2 (it)
CA (1) CA2600521A1 (it)
CO (1) CO6321131A2 (it)
EA (1) EA013015B1 (it)
IL (1) IL185879A0 (it)
IT (1) IT1362675B (it)
MA (1) MA29673B1 (it)
MX (1) MX2007011071A (it)
NI (1) NI200700222A (it)
NO (1) NO20075229L (it)
SA (1) SA06270133B1 (it)
TW (1) TW200719900A (it)
WO (1) WO2006097449A1 (it)
ZA (1) ZA200708754B (it)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0523040D0 (en) * 2005-11-11 2005-12-21 Cyclacel Ltd Combination
AU2013205135B2 (en) * 2006-10-28 2015-11-05 Forum Pharmaceuticals Inc. Inhibitors of histone deacetylase
JP5583406B2 (ja) * 2006-10-28 2014-09-03 メチルジーン インコーポレイテッド ヒストンデアセチラーゼの阻害剤
ATE484506T1 (de) * 2006-12-11 2010-10-15 Merck Sharp & Dohme Substituierte diazepin-sulfonamide als bombesin- rezeptor-subtyp-3-modulatoren
JP2011102240A (ja) * 2008-02-29 2011-05-26 Univ Of Tokyo 三環性化合物
US8202989B2 (en) 2009-01-12 2012-06-19 Council Of Scientific And Industrial Research One step process for the preparation of substituted 5, 10-dihydrodibenzo [b,e][1, 4]diazepine-11-ones
CA2795952A1 (en) * 2010-04-16 2011-10-20 Curis, Inc. Treatment of cancers having k-ras mutations
WO2012045194A1 (en) * 2010-10-09 2012-04-12 Abbott Laboratories Benzodiazepinones as fak inhibitors for treatment of cancer
RU2519546C1 (ru) * 2013-01-16 2014-06-10 Общество С Ограниченной Ответственностью "Биоинтегратор" (Ооо "Биоинтегратор") КОНЪЮГАТЫ И МАЛЫЕ МОЛЕКУЛЫ, ВЗАИМОДЕЙСТВУЮЩИЕ С РЕЦЕПТОРОМ CD16а
AU2014219042A1 (en) 2013-02-19 2015-09-17 Icahn School Of Medicine At Mount Sinai Tricyclic heterocycles as anticancer agents
WO2015138500A1 (en) 2014-03-11 2015-09-17 Icahn School Of Medicine At Mount Sinai Sulfonamides derived from tricyclyl-2-aminocycloalkanols as anticancer agents
EP3116857B1 (en) 2014-03-11 2019-02-06 Icahn School of Medicine at Mount Sinai Constrained tricyclic sulfonamides
US10047096B2 (en) 2014-11-25 2018-08-14 Bayer Pharma Aktiengesellschaft Substituted pyridobenzodiazepinone-derivatives and use thereof
WO2016089797A1 (en) 2014-12-05 2016-06-09 Merck Sharp & Dohme Corp. Novel tricyclic compounds as inhibitors of mutant idh enzymes
US10508108B2 (en) 2014-12-05 2019-12-17 Merck Sharp & Dohme Corp. Tricyclic compounds as inhibitors of mutant IDH enzymes
EP3226690B1 (en) 2014-12-05 2020-05-20 Merck Sharp & Dohme Corp. Novel tricyclic compounds as inhibitors of mutant idh enzymes
GB201510010D0 (en) 2015-06-09 2015-07-22 King S College London PDD and BPD compounds
GB201514928D0 (en) 2015-08-21 2015-10-07 King S College London PDD compounds
US20180339985A1 (en) 2015-08-21 2018-11-29 Femtogenix Limited Pdd compounds
CA2997784A1 (en) 2015-09-09 2017-03-16 Icahn School Of Medicine At Mount Sinai Heterocyclic constrained tricyclic sulfonamides as anti-cancer agents
CA2997769A1 (en) 2015-09-09 2017-03-16 Icahn School Of Medicine At Mount Sinai Heterocyclic constrained tricyclic sulfonamides as anti-cancer agents
WO2017044571A1 (en) * 2015-09-09 2017-03-16 Icahn School Of Medicine At Mount Sinai Tricyclic sultam sulfonamides as anticancer and neuroprotective agents
CN105806973B (zh) * 2016-03-10 2019-01-18 中国医学科学院肿瘤医院 Uplc-ms/ms法测定人血浆中莎巴比星及其代谢产物m3的血药浓度
CA3090493A1 (en) 2018-02-06 2019-08-15 The Board Of Trustees Of The University Of Illinois Substituted benzothiophene analogs as selective estrogen receptor degraders
KR102243465B1 (ko) * 2019-08-05 2021-04-22 리퓨어생명과학 주식회사 히스톤 아세틸트렌스퍼라제 p300 억제용 신규 화합물 및 이를 포함하는 항섬유화 조성물
KR102301274B1 (ko) * 2019-08-05 2021-09-14 리퓨어생명과학 주식회사 히스톤 아세틸트렌스퍼라제 p300 억제용 신규 화합물 및 이를 포함하는 항섬유화 조성물
WO2023020416A1 (zh) * 2021-08-16 2023-02-23 勤浩医药（苏州）有限公司 三环化合物、包含其的药物组合物及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6033110B2 (ja) * 1977-09-12 1985-08-01 帝国臓器製薬株式会社 ジベンズアゼピン誘導体
JPS53121780A (en) * 1977-04-01 1978-10-24 Teikoku Hormone Mfg Co Ltd Dibenzazepin derivatives and process for their preparation
AR035455A1 (es) * 2001-04-23 2004-05-26 Hoffmann La Roche Derivados triciclicos de alquilhidroxamato , procesos para su elaboracion, composiciones farmaceuticas que los contienen, y el uso de dichos compuestos en la preparacion de medicamentos
KR20050110612A (ko) * 2002-12-25 2005-11-23 다이이찌 세이야꾸 가부시기가이샤 디아민 유도체

Also Published As

Publication number Publication date
IL185879A0 (en) 2008-01-06
AP2007004170A0 (en) 2007-10-31
CO6321131A2 (es) 2011-09-20
NO20075229L (no) 2007-11-08
NI200700222A (es) 2008-07-24
MX2007011071A (es) 2007-10-08
CA2600521A1 (en) 2006-09-21
KR20080003336A (ko) 2008-01-07
AR053171A1 (es) 2007-04-25
US20080275023A1 (en) 2008-11-06
AU2006222883A1 (en) 2006-09-21
WO2006097449A1 (en) 2006-09-21
ZA200708754B (en) 2008-10-29
EA200701969A1 (ru) 2008-02-28
BRPI0608549A2 (pt) 2010-01-12
TW200719900A (en) 2007-06-01
JP2008533088A (ja) 2008-08-21
CN101142197A (zh) 2008-03-12
EP1863776A1 (en) 2007-12-12
ITFI20050042A1 (it) 2006-09-16
EA013015B1 (ru) 2010-02-26
SA06270133B1 (ar) 2009-05-16
MA29673B1 (fr) 2008-08-01

Similar Documents

Publication Publication Date Title
IT1362675B (it) N-idrossiammidi -sostituiti con gruppi triciclici come inibitori dell'istone deacelitasi,loro preparazione ed impiego in formulazioni farmaceutiche
IL201176A (en) 4-amino-1-h-pyrazolo [3,4- d] pyrimidine-3-ram-phenyl, a pharmaceutical containing them and their use in the preparation of a drug
RS20120139A3 (en) 8-[3-amino-piperidin-1-yl]-xanthines, the production thereof and the use of the same as medicaments
CR8642A (es) Compuestos, composiciones farmaceuticas y metodos para su uso en el tratameinto de desordenes metabolicos
IL192053A (en) 2-Admentiluria derivatives as selective inhibitors of 1hsd-β11 and their use in drug preparation
IL231576A (en) Derivatives of adamantyl-acetamide, the pharmaceutical compositions containing them and their use in the preparation of medicines
IL210452A (en) Annotations of dimethyl-oxo-dihydro- (pyridine-3-or-4-ram) -phenyl-6-methyl-6-phenyl- [1,3] -oxiazine-2-one
IL183360A (en) 12-aryl prostaglandin analogs, compositions comprising them and their use in the preparation of medicaments
WO2007098128A3 (en) Phenylephrine-containing liquid formulations
IL174647A (en) Pyrazolopyridines and analogs thereof, pharmaceutical compositions comprising them and their use in the manufacture of medicaments
IL184758A0 (en) New pharmaceutical compositions useful in the transmucosal administration of drugs
IL199187A (en) Indole history, pharmaceuticals including them and their use in the manufacture of medicines
IL196891A (en) Annals @@@ - Amino - @@@@@@@ - Tetrahydro - H9 - Carbazole - 9 - Yl) - Acetic Acid, Containing Pharmaceuticals
DK1603565T3 (da) Medikament omfattende en höjaktiv længevarende beta2-agonisk i kombination med andre aktive ingredienser
IL185484A0 (en) Aminopyrazole derivatives, their manufacture and use as pharmaceutical agents
ITPD20050242A1 (it) Bioconiugati antitumorali dell'acido ialuronico o dei suoi derivati, ottenibili per coniugazione chimica diretta o indiretta, e loro impiego in campo farmaceutico
CL2007002619A1 (es) Compuestos derivados de 3-aza-biciclo[4.1.0]heptano; composicion farmaceutica; y uso en el tratamiento de la depresion.
IL201730A (en) History 1h - Benzaimidazole – 2 – Il – Profile – Methyl – Amino – Ethyl – 5 – Aryl – Bicyclo [2.2.2] Oct – 5 – Ann – 2 – All, Pharmaceutical preparations containing them and their use in the preparation of drugs
FI20022129A7 (fi) Rasvahappokoostumus, sen valmistus ja käyttö
ITTO20040390A1 (it) Composizione, in particolare per uso farmaceutico, ad azione antiossidante, antinfiammatoria ed immunostimolante.
IL199168A0 (en) Indolizine derivatives and the use thereof as antidiabetics
CO6290689A2 (es) Derivados de 1,2,3,4-tetrahidropirrolo[1,2]pirazina-6-carboxamidas y de 2,3,4,5-tetrahidropirrol[1,2][1,4]-diazepina -7-carboxamidas su preparacion y su aplicacion en terapeutica
FR2920774B1 (fr) Nouveaux derives de n-phenul acatamide, inhibiteurs de l'enzyme soat-1, compositions pharmaceutiques et cosmetiques les contentant
EP2196463A4 (en) PREPARATION OF 5,6-DIMETHYLXANTHONE-4-ACETIC ACID, DERIVATIVES DERIVATED THEREOF AND PHARMACEUTICAL FORMULATIONS THEREOF
ITMI20041963A1 (it) "antagonisti non-peptidici della bradichinina e loro composizioni farmaceutiche"